Then, tumoral β-catenin signaling may impair antigen presentation and crosstalk, thereby creating a state of low antigenicity that could explain the lower PD-L1 CPS expression in those tumors with positive nuclear β-catenin, as observed in our study and also in other cancers [17]. This evidence concerns the gene CD274 and cancer.